The Technical Analyst
Albireo Pharma Inc [ALBO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Albireo Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $44.15
America/New_York / 2 mar 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 915.89 mill |
| EPS: | -6.66 |
| P/E: | -6.63 |
| Earnings Date: | May 15, 2023 |
| SharesOutstanding: | 20.74 mill |
| Avg Daily Volume: | 0.567 mill |
| RATING 2023-03-02 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.63 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.13x |
| Company: PE -6.63 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 43.22 - 45.08 ( +/- 2.11%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-03-02 | Chiswell David | Sell | 56 278 | Common Stock |
| 2023-03-02 | Chiswell David | Sell | 8 000 | Stock Option (Right to Buy) |
| 2023-03-02 | Chiswell David | Sell | 8 000 | Stock Option (Right to Buy) |
| 2023-03-02 | Chiswell David | Sell | 8 000 | Stock Option (Right to Buy) |
| 2023-03-02 | Chiswell David | Sell | 5 500 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -49.77 |
| Last 100 transactions |
| Buy: 1 059 000 | Sell: 2 762 067 |
Forecast:
01:40 - $45.47
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $44.15 (0.00% ) |
| Volume | 1.236 mill |
| Avg. Vol. | 0.567 mill |
| % of Avg. Vol | 218.05 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALBO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALBO
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Latest Press Releases
2023-12-14 08:00:00 - Press Release
Albireo Energy Sees Buildings In A Different Way As It Unveils New Brand Identity
Edison, n.j.--(business wire)-- #buildingsystemsperformance--albireo energy, a leading independent building controls and energy services provider and huron capital portfolio company, revealed its new brand positioning and identity in line with its focus on creating intelligent, high-performance buildings. “the new albireo energy brand represents our commitment to service innovation, excellence in project management, and unleashing our team of experts to help customers achieve maximum control over their buildings,” said larr.
2023-01-30 23:51:00 - Press Release
Shareholder Alert: Weiss Law Reminds Aqua, Lptx, Cnce, And Albo Shareholders About Its Ongoing Investigations
New york , jan. 30, 2023 /prnewswire/ -- if you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: joshua rubin, esq. weiss law 305 broadway, 7th floor new york, ny 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com evoqua water technologies corp. (nyse: aqua) weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of evoqua water technologies corp. (nyse: aqua) in connection with the proposed acquisition of aqua by xylem inc. ("xylem").
2022-11-01 08:30:00 - Press Release
Albireo To Present Late Breaking Bylvay® (odevixibat) Data At Aasld 2022
– oral late breaker with new results from positive phase 3 assert study in alagille syndrome (algs)
2022-10-31 08:30:00 - Press Release
Albireo To Report Q3 2022 Financial Results On November 8, 2022
Conference call and webcast to be held at 4:30 pm et conference call and webcast to be held at 4:30 pm et
2022-09-01 08:00:00 - Press Release
Albireo To Participate In Upcoming Investor Conferences
Boston, sept. 01, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in upcoming investor conferences:
Latest News
2023-03-01 11:18:01 - Zacks Investment Research
Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?
Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
2023-01-10 14:19:57 - Seeking Alpha
Albireo Pharma: Elucidating The Ipsen Buyout (Rating Upgrade)
Albireo Pharma, Inc. has entered into an agreement to get acquired by Ipsen. Bylvay is already approved for PFIC. Nevertheless, the stellar drug is poised to gain additional labels for Alagille syndrome and biliary atresia.
2023-01-09 11:00:00 - The Motley Fool
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday
2022-11-08 20:35:29 - Seeking Alpha
Albireo Pharma, Inc. (ALBO) Q3 2022 Earnings Call Transcript
Albireo Pharma, Inc. (NASDAQ:ALBO ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Hans Vitzthum - Managing Director, LifeSci Advisors Ron Cooper - President and Chief Executive Officer Jan Musin - Chief Scientific Officer, Head of R&D Pamela Stephenson - Chief Commercial Officer Simon Harford - Chief Financial Officer Conference Call Participants Miriam Nolan - Jefferies Brian Skorney - Baird Ritu Baral - Cowen Seamus Fernandez - Guggenheim Tim Lugo - William Blair Andreas Argyrides - Wedbush Securities Thomas Yip - H. C. Wainwright Operator Good afternoon.
2022-11-08 18:48:35 - Zacks Investment Research
Albireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimates
Albireo Pharma (ALBO) delivered earnings and revenue surprises of -1.61% and 1.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-11-01 08:30:00 - GlobeNewsWire
Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022
– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS)
2022-10-31 08:30:00 - GlobeNewsWire
Albireo to Report Q3 2022 Financial Results on November 8, 2022
Conference call and webcast to be held at 4:30 pm ET Conference call and webcast to be held at 4:30 pm ET
2022-10-12 18:44:15 - Seeking Alpha
Albireo: Strong Phase 3 Data Foretells More Upside
Sales for Bylvay's first approved indication is increasing. The company recently posted superb data for an orphan disease known as Alagille Syndrome.
2022-10-12 13:32:26 - Zacks Investment Research
Albireo (ALBO) Up on Results From Alagille Syndrome Study
Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.
2022-10-11 09:29:00 - Market Watch
Albireo's stock is up 10% on plans to seek FDA approval for drug for rare disorder
Shares of Albireo Pharma Inc. ALBO, +6.86% gained 10.4% in premarket trading on Tuesday after the company said it is seeking Food and Drug Administration approval to use its medication Bylvay as a treatment for Alagille syndrome, a rare inherited disorder that can result in liver damage. Albireo said a Phase 3 clinical trial evaluating the drug met its primary endpoint and a key secondary endpoint.